Targeting the Cell’s Powerhouse: Dr. Shaharyar Khan on Rivus Pharma’s Mitochondrial Approach to Cardiometabolic Diseases

In this episode, Ayesha spoke with Dr. Shaharyar Khan, co-founder and chief scientific officer at Rivus Pharmaceuticals.

Rivus is developing a new class of investigational medicines called controlled metabolic accelerators (CMAs) for cardiometabolic diseases like diabetes, heart disease, heart failure and MASH by targeting obesity.

Dr. Khan is an expert in the field of mitochondrial biology and the development of mitochondrial therapeutics. He has more than two decades of experience managing multidisciplinary teams of mitochondrial biologists, computational and medicinal chemists and clinicians.

Prior to his role at Rivus, Dr. Khan co-founded Gencia Biotech, where he also served as chief scientific officer and pioneered multiple drug discovery programs, including large and small molecules aimed at harnessing the unique role of mitochondria in the maintenance of cellular health.

Dr. Khan has a BA in philosophy and a PhD in neuroscience from the University of Virginia.

Tune in to hear about the novel mitochondrial approach to targeting cardiometabolic diseases that Dr. Khan is leading at Rivus Pharmaceuticals.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured